genital disease is suboptimal. Successful management of frequently recurrent genital HSV-2 disease in humans requires daily doses of acyclovir (ACV) in suppressive regimens lasting for months to years (12) . Although this approach is effective during the period of ACV administration, recurrences usually happen when treatment is discontinued (14) . Furthermore, some data suggest that ACV therapy of primary infections may limit development of the full extent of immune responses to HSV (3, 6) . Another problem with currently available therapy is the increasing frequency of ACV-resistant HSV strains usually associated with chronic or repeated courses of ACV (7, 11) , particularly in immunocompromised patients. Thus, it appears that mutant selection is enhanced when the host immune system is less capable of HSV-specific responses. Therefore, new strategies that incorporate both antiviral effects and enhancement of HSV-specific immune responses would be attractive as alternative or additive therapy for HSV-induced disease, particularly when the clinical situation involves an increased risk of ACV-resistant isolates.
We have previously shown that imiquimod (formerly R-837) induces in vivo antiviral effects principally as an immunomodulator that induces alpha interferon (IFN-a) and upregulates selected cell-mediated immune (CMI) responses to HSV in the guinea pig model (1, 9). Short-term (5-day) imiquimod regi- mens initiated soon (<36 h) after vaginal HSV-2 inoculation reduced the level of acute primary genital HSV disease and, unlike ACV, appeared to produce a partial reduction in the number of genital HSV recurrences after discontinuation of treatment (1, 9) in the guinea pig model.
In other guinea pig studies, we noted that imiquimod produces an adjuvant effect with an HSV mixed-glycoprotein vaccine against primary HSV infection, apparently by enhancing antigen presentation and upregulating certain HSV-specific T-cell and cytokine responses (4). We had previously correlated enhancement of these responses to inhibition of recurrent HSV disease in guinea pigs (2, 13 In vitro IL-2 production assays. Supernatants were collected at 48 h of incubation of PBMCs with whole HSV antigen and control antigen for assays of interleukin 2 (IL-2) activity. The IL-2 bioassay involved measuring [3H]thymidine incorporation into 4 x 103 cells of the IL-2-dependent murine cell line CTLL-2 after 20 h of culture and a 4-h thymidine pulse as previously described (1, 9). Relative IL-2 production was measured as the activity in HSV antigen-stimulated wells minus that in control antigen-stimulated wells compared with a known standard of 100 U of IL-2 (Cetus Corporation).
PBMC-mediated MHC-unrestricted cytolysis assays of HSV targets. Major histocompatibility complex (MHC) unrestricted cytolytic activity against HSV-infected HFF targets was assayed (in the 5-day experiment only) by standard 51Cr release assays as previously described (9, 10 14 after inoculation) were also observed in the randomized placebo and imiquimod groups for both the 5-and 21-day treatment studies (data not shown).
Effect on recurrent genital disease. As shown in Fig. 1 disease during treatment and in 4 of the subsequent 5 weeks of observation. Similarly, when recurrences were analyzed for the entire observation period, the overall reductions in mean recurrent disease were 16% with imiquimod for 5 days (0.29 ± 0.14 versus 0.35 ± 0.14 lesion days/week for imiquimod and placebo recipients, respectively [P > 0.2]) and 67% with imiquimod for 21 days (0.35 ± 0.17 versus 1.05 ± 0.19 lesion days/week for imiquimod and placebo recipients, respectively [P < 0.0001]).
HSV-specific immune responses. Both 5-and 21-day imiquimod recipients exhibited lower HSV-specific antibody levels in the period soon after cessation of suppressive therapy (Fig. 2) . The 5-day imiquimod group exhibited a rebound in antibody response eventually surpassing that for the placebo group ( Fig. 2A) . In contrast the 21-day imiquimod group had persistently lower antibody titers at each assay point (Fig. 2B) .
Assays for MHC-unrestricted cytolytic activity against HSVinfected targets were performed only in animals from the 5-day experiment. There were no differences in cytolytic activity between HSV-infected groups, whether they received imiquimod or not, but all HSV-infected animals (both placebo and imiquimod recipients) exhibited significantly higher levels of activity against HSV targets than uninfected control animals receiving placebo (data not shown).
In vitro IL-2 production by phytohemagglutinin-stimulated PBMCs did not differ significantly between any HSV-infected treatment groups at any time in the study (data not shown). HSV antigen-stimulated PBMCs from uninfected placebo controls produced <5 U of IL-2 on each assay day (data not shown). HSV antigen-stimulated PBMCs from HSV-infected 5-day imiquimod recipients produced IL-2 activity similar to that of HSV-infected 5-day placebo recipients on days 14, 21, 28, and 49 after infection (Fig. 3A) ; i.e., there was increasing in vitro IL-2 production with time after infection in both HSVinfected groups. This differed from the results in the 21-day therapy groups, where pretreatment (day-14) IL-2 activity in supernatants of HSV antigen-stimulated PBMCs did not differ, but IL-2 activity was significantly higher in 21-day imiquimod recipients (Fig. 3B ) than in 21-day placebo recipients on days 35 and 60 (P < 0.001).
Despite randomization, HSV-stimulated proliferative response levels in the HSV-infected 5-day placebo recipients were higher than those in the HSV-infected imiquimod recipients prior to treatment (P < 0.01) ( and imiquimod recipients exhibited similar responses to HSV antigen only in the pretreatment assay. After treatment, the mean proliferative response level to HSV antigen was significantly higher in the imiquimod group than in the placebo group on day 35 (P < 0.001) and on day 60 (P < 0.001) ( Table  1) . Circulating IFN. Pretreatment levels of circulating IFN activity were similar and averaged below 20 U/ml in all groups. Elevated circulating IFN activity levels were detected in both imiquimod groups only during treatment (P < 0.001) on each treatment day assayed, i.e., days 15 to 20 for the 5-day group and days 28 and 35 for the 21-day group, returning to baseline soon after cessation of therapy (Table 2) .
Latent neural HSV in tissue obtained after treatment. Five-day recipients of imiquimod and placebo had similar rates of detectable latent HSV-2 by classic cocultivation of ganglia or spinal cord when sacrificed on day 90 after HSV inoculation: 75% (6 of 8) for drug recipients compared with 88% (7 of 8) for placebo recipients. This was also true for 21-day recipients: 78% (7 of 9) for imiquimod recipients and 89% (8 of 9) for placebo recipients.
DISCUSSION
One goal of suppressive therapy for frequently recurrent genital HSV is continued suppression after therapy is discontinued. Our initial investigations of imiquimod treatment of primary HSV-2 genital disease showed that, unlike ACV (5, 6), imiquimod not only reduced the level of acute HSV genital disease but also reduced the number of subsequent recurrences of the disease. While imiquimod-treated animals developed reduced HSV-2 antibody responses (1, 9), HSV-specific cell-mediated and cytokine (IL-1 and IL-2) responses were enhanced, despite reduced duration and quantity of HSV replication. We therefore evaluated imiquimod for treatment of recurrent HSV disease, postulating that the level of disease would be reduced by IFN induced during therapy and later by upregulated HSV-specific cell-mediated immune responses. In this study, we showed that 21 days of imiquimod therapy not only reduced the number of recurrences during therapy but also reduced the number of recurrences for 5 of the 6 weeks after therapy was stopped.
The reduced level of recurrent genital disease observed in the 21-day imiquimod recipients appeared associated with upregulation of selected cell-mediated and IL-2 responses to HSV, similar to that which we have reported with vaccine immunotherapy (2, 13). No overall disease reduction or posttreatment effect was noted with the shorter (5-day) imiquimod suppressive regimen. However, recurrence rates in the 5-day placebo control group were less than half of the normal historically observed rate in placebo-treated HSV-infected animals (1, 2, 5, 9, 13). On the basis of this and the significantly higher level of pretreatment HSV-specific proliferative T-cell responses, the animals randomized to the placebo group inadvertently constituted a group of relative hyperresponders to HSV compared with the imiquimod group, despite similar primary clinical disease profiles. This appeared to reduce the level of disease in the control population and may have reduced our power to detect a clinical posttreatment beneficial effect with the 5-day drug treatment. However, no immunologic enhancement was detected after short-course imiquimod therapy except for a late antibody enhancement which did not correlate with clinical benefit. Reasons for the unusually high percentage of hyperresponding naturally HSV-resistant animals in one study arm despite randomization are unclear. The number of such naturally HSV-resistant animals among our study groups is usually <10% of all animals from this supplier. Another potential explanation of the difference between background recurrences in the 5-versus 21-day experiments is that the 5-day study was also performed temporally before the 21-day study because of housing limitations. Thus, while all animals were from the same supplier, the 5-and 21-day groups were obtained at different times. It is possible that some posttreatment benefit might have been detected after 5 days of imiquimod therapy if the hyperresponsive animals had been evenly distributed to both the placebo group and the imiquimod group, but our current data do not support such a conclusion.
The mechanism for the posttreatment protective effect, observed after 21 days of imiquimod therapy, cannot be definitively understood from the selective survey of immune function provided by the two experiments reported here. However, it seems reasonable to attribute most if not all of the reduction in number of recurrences during therapy with either imiquimod regimen to the endogenous IFN induced by treatment. Another mechanism must be postulated for the benefit observed in the 21-day imiquimod recipients, because circulating IFN levels rapidly returned to baseline less than a week after drug administration was stopped.
The mechanism for this longer posttherapy suppression could have been drug-induced reduction in the level of latent HSV in ganglia, yielding fewer reactivation events. However, the posttreatment protection in the 21-day imiquimod recipients did not correlate with detectable differences in latent infection of ganglia or spinal cord by classic cocultivation methods. This suggests that immune modification played a role in the extended beneficial effect. We postulate that the posttreatment effect resulted from imiquimod's inducing an immune modulation weighted toward protective responses not ordinarily produced by natural infection. Possible avenues of such immune modulation include humoral, cytokine, and/or cell-mediated responses. From the current data and our previous studies (2, 13), we further postulate that enhanced cytokine and cell-mediated responses are most likely responsible for the extended benefits. 
